Academy

Ian Krop, MD - Metastatic HER2+ BC

Nancy Lin, MD - Brain Mets

Priyanka Sharma, MD - Treatment Approaches for Metastatic TNBC

Panel Discussion

Antonio Giordano, MD - Novel Cell Cycle Agents

Rita Nanda, MD - Future of Bispecifics

Virginia Kaklamani, MD - Future of Oral SERDs

Seth Wander, MD - Novel Strategies for targeting PI3K

Panel Discussion

Joseph Sparano, MD - The Role of OFS and Genomic Assays in Premenopausal

Stefania Morganti, MD - Future of ctDNA

Panel Discussion

Heather McArthur, MD - Optimization of Immunotherapy in Early-Stage Breast Cancer

Mothaffar Rimawi, MD - Treatment of Early Stage HER2+ Breast Cancer

Erica Mayer, MD - Adjuvant cdk 4/6 Inhibition: Who Needs Which Agent and For How Long?

Richard Zellars, MD - Postmastectomy XRT: Who Needs it?

Panel Discussion

Rachel Freedman, MD - Optimal Assessment and Therapeutic Approaches for Older Patients with Breast Cancer

Filipa Lynce, MD - Treatment of Inflammatory Breast Cancer

Panel Discussion

Paolo Tarantino, MD - Role of ADCs

Paolo Tarantino, MD - Debate: Should ADCs be Sequenced?: Yes

Laura Huppert, MD - Debate: Should ADCs be Sequenced?: No

Alastair Thompson, MD - What we have learned from 30 Years of Performing SLN Biopsy

Panel Discussion